Programs

Scroll to explore

Immuno-oncology programs

GPCRs constitute strategic targets mediating immunosuppression. The company exploits its expertise in the field to move forward small molecule and antibody based-assets toward the clinic.

Immuno-oncology

EP4 receptor antagonist

Discover more

A2aR/A2bR antagonist

Merck is one of Domain Therapeutics’s partners
Discover more

Anti-CCR8 depleting antibody

Discover more

PAR2 antagonist

Discover more

Undisclosed GPCR targets

Discover more